Last $8.03 USD
Change Today +0.14 / 1.77%
Volume 5.5M
PDLI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Open
$8.01
Previous Close
$7.89
Day High
$8.29
Day Low
$7.90
52 Week High
09/2/14 - $10.26
52 Week Low
02/5/14 - $7.38
Market Cap
1.3B
Average Volume 10 Days
4.7M
EPS TTM
$1.73
Shares Outstanding
160.6M
EX-Date
12/3/14
P/E TM
4.6x
Dividend
$0.60
Dividend Yield
7.47%
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 03/3/14
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.2M
Chief Financial Officer and Vice President
Total Annual Compensation: $323.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $659.7K
Chief Accounting Officer and Controller
Total Annual Compensation: $105.0K
Deputy General Counsel and Assistant Secretar...
Total Annual Compensation: $509.6K
Compensation as of Fiscal Year 2013.

pdl biopharma inc (PDLI) Key Developments

Pomerantz Law Firm Files Class Action Lawsuit against PDL BioPharma, Inc. and Certain Officers

Pomerantz LLP has filed a class action lawsuit against PDL BioPharma, Inc. and certain of its officers. The class action, filed in United States District Court, District of Nevada, and docketed under 14-cv-01526, is on behalf of a class consisting of all persons or entities who purchased PDL BioPharma securities between November 6, 2013 and September 16, 2014, inclusive. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the company's business, operations, prospects and performance. Specifically, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: the company was overstating its: total revenues; royalty revenues; net income; and net cash provided by operating activities; the company was understating its operating expenses; the company failed to properly classify royalty and milestone payments due under an agreement with Depomed; and the company's financial statements were materially false and misleading at all relevant times.

PDL Biopharma, Inc. Announces Resignation of Ernst & Young LLP as Auditor

On September 11, 2014, PDL BioPharma, Inc. was orally notified by its independent registered accounting firm, Ernst & Young LLP (EY) that it was resigning effective September 11, 2014. The resignation was confirmed in a letter delivered to the Company on September 15, 2014. The reports of EY on the Company's financial statements for each of the two fiscal years ended December 31, 2012 and 2013 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

PDL BioPharma, Inc. Announces Revenue Guidance for the Third Quarter Ending September 30, 2014

PDL BioPharma, Inc. announced revenue guidance for the third quarter ending September 30, 2014. For the period, the company expected revenue of approximately $165 million as compared with actual revenue of $100.2 million for the third quarter of 2013, an approximate 65% increase.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $8.03 USD +0.14

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.50 EUR +0.05
BioInvent International AB kr3.19 SEK 0.00
Genmab A/S kr237.80 DKK +4.00
XOMA Corp $4.54 USD -0.04
View Industry Companies
 

Industry Analysis

PDLI

Industry Average

Valuation PDLI Industry Range
Price/Earnings 4.9x
Price/Sales 2.9x
Price/Book 4.3x
Price/Cash Flow 4.6x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.